Pricing Log in Create free account

Silo Pharma, Inc. (SILO) vs Virax Biolabs Group Limited (VRAX)

Silo Pharma, Inc. and Virax Biolabs Group Limited are both Biotechnology companies. Virax Biolabs Group Limited is the larger, with a market value of $2.2M against $1.9M — 1.1× the size. Across the 10 metrics below, Virax Biolabs Group Limited leads on 8 and Silo Pharma, Inc. on 2.

Valuation

Metric SILO VRAX Biotechnology median
P/E n/m n/m 8.50
P/S 18.00 n/m 9.71
P/B 0.27 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.90 0.86 0.64
EV/Sales (54.56) n/m 9.21
Earnings yield (369.34%) (367.59%) (33.15%)
Free cash flow yield (302.55%) 0.00% (25.50%)

Profitability

Metric SILO VRAX Biotechnology median
Gross margin 11.81% — 65.16%
Operating margin 0.00% — 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (91.23%) 0.00% (56.36%)
Return on assets (70.96%) 0.00% (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric SILO VRAX Biotechnology median
Revenue growth (TTM) 0.00% — 6.02%
EPS growth (last fiscal year) 57.98% 68.79% 30.26%
Revenue growth, 5-year CAGR 12.17% (36.88%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric SILO VRAX Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.36 9.97 4.72
Net debt to EBITDA 1.61 1.08 0.96

Dividend

Metric SILO VRAX Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric SILO VRAX Biotechnology median
Market cap 1.91m 2.18m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack